

## Erratum

**Erratum: Vink P, Delgado Mingorance I, Maximiano Alonso C, et al. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial. *Cancer* 2019;125:1301-1312.**

In the following paragraph of the Discussion section on page 1310:

In healthy adults receiving 2 doses of RZV, humoral immune responses increase from M1 to M2.<sup>31</sup> However, in our ST population, these responses decreased from M1 to M2 in the RZV-PreChemo group and remained unchanged in the RZV-OnChemo group. Presumably, this observation is secondary to immunosuppression from chemotherapy administration and the short courses of dexamethasone, which is frequently used to prevent nausea and vomiting. We hypothesized that these immunosuppressive agents impair B cell function and antibody production. Indeed, preclinical studies in dogs support the hypothesis that humoral immune response is lowered by the presence of cancer, compared with healthy matched animals, and that B cell response is further impaired by chemotherapy.<sup>34</sup> Immune responses to the recombinant Wilms' tumor 1 (WT1) protein combined with the immunostimulant AS15 (GSK) were also found to be blunted by concomitant administration of chemotherapy in WT1-positive breast cancer patients.<sup>35</sup>

Reference 35 in the end of the paragraph is incorrect. The correct reference to be put here should be:

Higgins M, Curigliano G, Dieras V, et al. Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study. *Breast Cancer Res Treat* 2017;162:479-88. (doi: 10.1007/s10549-017-4130-y).

The authors regret this error.

DOI: 10.1002/cncr.32842